The current state of GPCR‐based drug discovery to treat metabolic disease

One approach of modern drug discovery is to identify agents that enhance or diminish signal transduction cascades in various cell types and tissues by modulating the activity of GPCRs. This strategy has resulted in the development of new medicines to treat many conditions, including cardiovascular disease, psychiatric disorders, HIV/AIDS, certain forms of cancer and Type 2 diabetes mellitus (T2DM). These successes justify further pursuit of GPCRs as disease targets and provide key learning that should help guide identifying future therapeutic agents. This report reviews the current landscape of GPCR drug discovery with emphasis on efforts aimed at developing new molecules for treating T2DM and obesity. We analyse historical efforts to generate GPCR‐based drugs to treat metabolic disease in terms of causal factors leading to success and failure in this endeavour.

[1]  M. Rodbell.  The problem of identifying the glucagon receptor. , 1973, Federation proceedings.

[2]  J. Raufman,et al.  Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. , 1992, The Journal of biological chemistry.

[3]  L. Lasagna,et al.  Long‐term weight control study I (weeks 0 to 34) , 1992, Clinical pharmacology and therapeutics.

[4]  F J Grant,et al.  Expression cloning and signaling properties of the rat glucagon receptor. , 1993, Science.

[5]  C. Bogardus,et al.  Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene. , 1995, The New England journal of medicine.

[6]  G. Gessa,et al.  Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. , 1998, Life sciences.

[7]  B. Lowell,et al.  Mice expressing human but not murine beta3-adrenergic receptors under the control of human gene regulatory elements. , 1998, Diabetes.

[8]  P. Burn,et al.  Melanocortin-4 receptor: A novel signalling pathway involved in body weight regulation , 1999, International Journal of Obesity.

[9]  S. Toubro,et al.  Effect of a 28-d treatment with L-796568, a novel beta(3)-adrenergic receptor agonist, on energy expenditure and body composition in obese men. , 2002, The American journal of clinical nutrition.

[10]  Rachel L. Batterham,et al.  Gut hormone PYY3-36 physiologically inhibits food intake , 2002, Nature.

[11]  M. Fujimiya,et al.  Antagonism of ghrelin receptor reduces food intake and body weight gain in mice , 2003, Gut.

[12]  B. Lowell,et al.  β-Adrenergic Receptors, Diet-induced Thermogenesis, and Obesity* , 2003, Journal of Biological Chemistry.

[13]  J. Holst,et al.  Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. , 2004, Diabetes.

[14]  N. Porksen,et al.  Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. , 2004, The Journal of clinical investigation.

[15]  Bengt Långström,et al.  Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. , 2006, Cell metabolism.

[16]  D. Drucker.  The biology of incretin hormones. , 2006, Cell metabolism.

[17]  R. Lefkowitz,et al.  Seven transmembrane receptors: something old, something new , 2007, Acta physiologica.

[18]  A. A. Jensen,et al.  Allosteric Modulation of the Calcium-Sensing Receptor , 2007, Current neuropharmacology.

[19]  B. Ahrén.  Dipeptidyl Peptidase-4 Inhibitors , 2007, Diabetes Care.

[20]  Bonnie J. Ahr.  Dipeptidyl Peptidase-4 Inhibitors Clinical data and clinical implications , 2007 .

[21]  P. Piazza,et al.  Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients. , 2007, Diabetes & metabolism.

[22]  Lawrence A Leiter,et al.  Stimulation of Cholecystokinin‐A Receptors With GI181771X does not Cause Weight Loss in Overweight or Obese Patients , 2008, Clinical pharmacology and therapeutics.

[23]  H. Davis,et al.  Lack of FFAR1/GPR40 Does Not Protect Mice From High-Fat Diet–Induced Metabolic Disease , 2008, Diabetes.

[24]  K. Gadde,et al.  Rational Design of a Combination Medication for the Treatment of Obesity , 2009, Obesity.

[25]  Y. Tao.  Mutations in melanocortin-4 receptor and human obesity. , 2009, Progress in molecular biology and translational science.

[26]  T. Kowalski,et al.  GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis. , 2009, The Journal of endocrinology.

[27]  R. DeFronzo,et al.  Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes , 2009, Diabetes Care.

[28]  G. Bray,et al.  Potent and Selective Agonism of the Melanocortin Receptor 4 With MK‐0493 Does Not Induce Weight Loss in Obese Human Subjects: Energy Intake Predicts Lack of Weight Loss Efficacy , 2009, Clinical pharmacology and therapeutics.

[29]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[30]  S. Kliewer,et al.  The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling. , 2011, Molecular endocrinology.

[31]  P. Rorsman,et al.  The Effects of TAK-875, a Selective G Protein-Coupled Receptor 40/Free Fatty Acid 1 Agonist, on Insulin and Glucagon Secretion in Isolated Rat and Human Islets , 2012, Journal of Pharmacology and Experimental Therapeutics.

[32]  Sean P. Brown,et al.  A Potent Class of GPR40 Full Agonists Engages the EnteroInsular Axis to Promote Glucose Control in Rodents , 2012, PloS one.

[33]  L. Xi,et al.  Effects of JNJ‐38431055, a novel GPR119 receptor agonist, in randomized, double‐blind, placebo‐controlled studies in subjects with type 2 diabetes , 2012, Diabetes, obesity & metabolism.

[34]  R. Coppari,et al.  Direct leptin action on POMC neurons regulates glucose homeostasis and hepatic insulin sensitivity in mice. , 2012, The Journal of clinical investigation.

[35]  Randy J. Seeley,et al.  Cooperation between brain and islet in glucose homeostasis and diabetes , 2013, Nature.

[36]  Sang-Uk Kang,et al.  GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119. , 2013, Drug discovery today.

[37]  D. Nunez,et al.  Safety, Pharmacokinetics, and Pharmacodynamic Effects of a Selective TGR5 Agonist, SB‐756050, in Type 2 Diabetes , 2013, Clinical pharmacology in drug development.

[38]  J. Jaén,et al.  Evaluation of AMG 076, a potent and selective MCHR1 antagonist, in rodent and primate obesity models , 2013, Pharmacology research & perspectives.

[39]  Bin Yang,et al.  Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans , 2013, Science Translational Medicine.

[40]  J. Holst,et al.  Exaggerated Glucagon-Like Peptide 1 Response Is Important for Improved β-Cell Function and Glucose Tolerance After Roux-en-Y Gastric Bypass in Patients With Type 2 Diabetes , 2013, Diabetes.

[41]  J. Shaw,et al.  Diabetes: a 21st century challenge. , 2014, The lancet. Diabetes & endocrinology.

[42]  R. Evans,et al.  A Gpr120 Selective Agonist Improves Insulin Resistance and Chronic Inflammation , 2014, Nature Medicine.

[43]  L. Corsino,et al.  Gut Hormone Pharmacology of a Novel GPR119 Agonist (GSK1292263), Metformin, and Sitagliptin in Type 2 Diabetes Mellitus: Results from Two Randomized Studies , 2014, PloS one.

[44]  D. Dodick,et al.  Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study , 2014, The Lancet Neurology.

[45]  Kira B. Harris,et al.  Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus , 2015, Therapeutic advances in endocrinology and metabolism.

[46]  K. Kaku,et al.  Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial , 2015, Diabetes, obesity & metabolism.

[47]  F. Gao,et al.  GSK256073 acutely regulates NEFA levels via HCA2 agonism but does not achieve durable glycaemic control in type 2 diabetes. A randomised trial. , 2015, European journal of pharmacology.

[48]  Kak‐Shan Shia,et al.  A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis , 2015, Diabetes, obesity & metabolism.

[49]  Jianhua Shen,et al.  Discovery of Intestinal Targeted TGR5 Agonists for the Treatment of Type 2 Diabetes. , 2015, Journal of medicinal chemistry.

[50]  Tamara S. Roman,et al.  New genetic loci link adipose and insulin biology to body fat distribution , 2014, Nature.

[51]  R. Cone,et al.  RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals. , 2015, The Journal of clinical endocrinology and metabolism.

[52]  Bryan L Roth,et al.  Integrated Approaches for Genome-wide Interrogation of the Druggable Non-olfactory G Protein-coupled Receptor Superfamily* , 2015, The Journal of Biological Chemistry.

[53]  A. Mancini,et al.  GPR40 agonists for the treatment of type 2 diabetes: life after ‘TAKing’ a hit , 2015, Diabetes, obesity & metabolism.

[54]  K. Clément,et al.  Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist. , 2016, The New England journal of medicine.

[55]  H. Stark,et al.  Cherry-picked ligands at histamine receptor subtypes , 2016, Neuropharmacology.

[56]  Elizabeth G. Mietlicki-Baase.  Amylin-mediated control of glycemia, energy balance, and cognition , 2016, Physiology & Behavior.

[57]  P. Sexton,et al.  Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes , 2016, Pharmacological Reviews.

[58]  G. Shulman,et al.  The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. , 2016, The Journal of clinical investigation.

[59]  D. Drucker.  The Cardiovascular Biology of Glucagon-like Peptide-1. , 2016, Cell metabolism.

[60]  Lawrence A Leiter,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.

[61]  P. Blandina,et al.  The histaminergic system as a target for the prevention of obesity and metabolic syndrome , 2016, Neuropharmacology.

[62]  R. Unger,et al.  Clinical Trials, Triumphs, and Tribulations of Glucagon Receptor Antagonists , 2016, Diabetes Care.

[63]  C. Buning,et al.  G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges. , 2016, Journal of medicinal chemistry.

[64]  Tudor I. Oprea,et al.  A comprehensive map of molecular drug targets , 2016, Nature Reviews Drug Discovery.

[65]  Arthur Christopoulos,et al.  THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein‐coupled receptors , 2017, British journal of pharmacology.

[66]  Adam J Pawson,et al.  THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes , 2017, British journal of pharmacology.

[67]  Adam J Pawson,et al.  THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Transporters , 2017, British journal of pharmacology.

[68]  M. Tschöp,et al.  The New Biology and Pharmacology of Glucagon. , 2017, Physiological reviews.

[69]  Adam J Pawson,et al.  THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Nuclear hormone receptors , 2017, British journal of pharmacology.

[70]  T. Schwartz,et al.  Gq and Gs signaling acting in synergy to control GLP-1 secretion , 2017, Molecular and Cellular Endocrinology.

[71]  F. Willard,et al.  Regulation of Endogenous (Male) Rodent GLP-1 Secretion and Human Islet Insulin Secretion by Antagonism of Somatostatin Receptor 5 , 2017, Endocrinology.

[72]  A. Howard,et al.  GPR40 reduces food intake and body weight through GLP-1. , 2017, American journal of physiology. Endocrinology and metabolism.

[73]  Margaret S. Wu,et al.  GPR120 suppresses adipose tissue lipolysis and synergizes with GPR40 in antidiabetic efficacy[S] , 2017, Journal of Lipid Research.

[74]  Alasdair J. G. Gray,et al.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY , 2017, Nucleic Acids Res..